Six important updates in cervical cancer

The addition of bevacizumab to chemotherapy continued to show significant survival benefits among women with advanced cervical cancer. Patients who received the combination therapy lived 3.5 months longer than those assigned chemotherapy alone.
High-dose brachytherapy delivered in four fractions of 7 Gy conferred a higher rate of 5-year tumour control than two fractions of 9 Gy among patients with cervical cancer undergoing external beam radiotherapy.
Neoadjuvant chemotherapy followed by radical surgery did not improve outcomes compared with cisplatin-based concurrent chemoradiation for women with locally advanced squamous carcinoma of the cervix.